
	For the thirteen weeks ended				For the thirty-nine weeks ended
	September 27, 2026		September 28, 2025		September 27, 2026		September 28, 2025
Numerator:
Net income (loss)	$	7,823	$	(806)	$	12,650	$	12,874
Denominator:
Weighted average common shares outstanding - basic	120,329,310		119,405,911		120,143,868		119,140,257
Dilutive effect of potential common shares from RSUs	395,298		—		991,810		462,500
Dilutive effect of potential common shares from PSUs	152,685		—		208,555		208,230
Weighted average common shares outstanding - diluted	120,877,293		119,405,911		121,344,233		119,810,987
Earnings per share:
Basic	$	0.07	$	(0.01)	$	0.11	$	0.11
Diluted	$	0.06	$	(0.01)	$	0.10	$	0.11

The following outstanding shares of Common Stock equivalents were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive. Warrants to purchase shares of Common Stock having an exercise price greater than the average share market price are excluded from the calculation of diluted earnings per share.


	For the thirteen weeks ended		For the thirty-nine weeks ended
	September 27, 2026	September 28, 2025	September 27, 2026	September 28, 2025
Anti-dilutive shares excluded from calculation of diluted EPS:
Warrants	2,894,501	14,633,311	10,676,897	14,633,311
Stock options	333,447	437,268	333,447	437,268
Restricted stock units	134,143	3,600,584	189,788	3,138,084
Performance stock units	2,122,804	2,697,537	2,065,312	2,489,307
Unvested earn-out shares	1,093,750	1,093,750	1,093,750	1,093,750
Total anti-dilutive shares	6,578,645	22,462,450	14,359,194	21,791,720